Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split

Core Viewpoint - Psyence Biomedical Ltd. has announced a 1-for-6.25 share consolidation, effective January 20, 2026, following prior approvals for share consolidations at different ratios [1][2][3]. Group 1: Share Consolidation Details - The share consolidation will combine every 6.25 issued and outstanding shares into one common share, resulting in a total of 1,022,177 common shares outstanding post-consolidation [3]. - The consolidation was approved by shareholders at a Special Meeting on April 16, 2025, allowing the Board of Directors to implement a consolidation ratio of up to 1-for-50 [1]. - The Company had previously authorized a 1-for-7.97 consolidation ratio, which was implemented on May 5, 2025 [1]. Group 2: Trading and Adjustments - Post-consolidation, the common shares will continue to trade under the symbol "PBM" on the Nasdaq Capital Market, with a new CUSIP number 74449F407 [2]. - The number of shares and the exercise price of outstanding warrants and other equity instruments will be adjusted proportionately according to their respective terms [3]. Group 3: Shareholder Impact - No fractional shares will be issued; any resulting fractions will be rounded to the nearest whole share [4]. - The consolidation affects all shareholders uniformly, with minor adjustments for fractional shares [4]. - Beneficial holders may experience delays in the reflection of the consolidation in their accounts, depending on their broker's procedures [4][5]. Group 4: Company Overview - Psyence Biomedical Ltd. is a biopharmaceutical company specializing in psychedelic-based therapeutics, focusing on nature-derived psilocybin and ibogaine-based medicines [6]. - The Company aims to address unmet mental health needs through evidence-based approaches in developing safe and effective treatments [6].